Inhalable TFRC-Targeted Extracellular Vesicles Delivery of siTGF-β1 Alleviates Pulmonary Fibrosis via Dual Inhibition of Ferroptosis and Fibroblast Activation

Background: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disorder marked by excessive extracellular matrix deposition and limited treatment options. Ferroptosis has emerged as a critical driver of epithelial injury and fibrogenesis, while fibroblast activation further accelerates pathological remodeling. The transferrin receptor (TFRC), aberrantly upregulated in both alveolar epithelial cells and fibroblasts during fibrosis, represents a promising target for precision therapy. Methods: An engineered extracellular vesicle (EV) platform was developed using human umbilical cord mesenchymal stem cell-derived vesicles (HucMSC-EVs). By conjugating a T7 peptide for TFRC targeting and encapsulating small interfering RNA against transforming growth factor-beta 1 (siTGF-β1) through electroporation, a dual-functional nanocomplex (T7-EV/siTGF-β1) was generated. Its delivery efficiency, molecular effects, and therapeutic outcomes were systematically evaluated in vitro and in bleomycin-induced pulmonary fibrosis mouse models. Results: T7-EV/siTGF-β1 achieved targeted uptake by epithelial cells and fibroblasts, efficiently silencing TGF-β1 expression. Treatment significantly inhibited iron accumulation, reactive oxygen species (ROS) generation, and lipid peroxidation, thereby suppressing ferroptosis. Concurrently, the nanocomplex reduced myofibroblast activation, collagen deposition, and fibrotic remodeling, ultimately improving lung histopathology and respiratory function. Importantly, aerosolized administration enabled preferential lung accumulation with minimal off-target distribution and excellent biocompatibility. Conclusion: This study demonstrates that simultaneous inhibition of epithelial ferroptosis and fibroblast activation via TFRC-targeted EV-mediated siRNA delivery effectively mitigates pulmonary fibrosis. T7-EV/siTGF-β1 thus offers a synergistic and clinically translatable strategy for treating IPF and other fibrotic lung diseases.

• Publication year

  2026

• Venue

  International Journal of Nanomedicine

• Publication date

  2026-02-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.2147/ijn.s568106
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhalable Nucleic Acid Therapeutics for Chronic Pulmonary Disease: Progress, Challenges, and Prospects.

  2025cited by this paper
• EVs Biodistribution and Antifibrotic Impact in Aged Lung Fibrosis Model

  2025cited by this paper
• Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label, phase I clinical trial

  2024cited by this paper
• Human placental mesenchymal stromal cell‐derived small extracellular vesicles as a treatment for severe COVID‐19: A double‐blind randomized controlled clinical trial

  2024cited by this paper
• Impaired GPX4 activity elicits ferroptosis in alveolar type II cells promoting PHMG-induced pulmonary fibrosis development.

  2024cited by this paper
• A deep insight into ferroptosis in lung disease: facts and perspectives

  2024cited by this paper
• Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity

  2024cited by this paper
• The Landscape of Nanoparticle-based siRNA Delivery and Therapeutic Development.

  2024cited by this paper
• Fibroblast-derived extracellular vesicles contain SFRP1 and mediate pulmonary fibrosis

  2024cited by this paper
• Iron-laden macrophage-mediated paracrine pro-fibrotic signaling induces lung fibroblast activation.

  2024cited by this paper
• Extracellular vesicles: emerging roles, biomarkers and therapeutic strategies in fibrotic diseases

  2023cited by this paper
• TGF-β mediated drug resistance in solid cancer.

  2023cited by this paper
• Combinatorial development of nebulized mRNA delivery formulations for the lungs

  2023cited by this paper
• Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors.

  2023cited by this paper
• Gene deletion of long-chain acyl-CoA synthetase 4 attenuates xenobiotic chemical-induced lung injury via the suppression of lipid peroxidation

  2023cited by this paper
• Diesel exhaust PM2.5 greatly deteriorates fibrosis process in pre-existing pulmonary fibrosis via ferroptosis.

  2022cited by this paper
• Inhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model

  2022influential reference
• Exosomal thioredoxin-1 from hypoxic human umbilical cord mesenchymal stem cells inhibits ferroptosis in doxorubicin-induced cardiotoxicity via mTORC1 signaling.

  2022cited by this paper
• Liposomal UHRF1 siRNA shows lung fibrosis treatment potential through regulation of fibroblast activation

  2022cited by this paper
• Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial

  2022cited by this paper
• UHRF1-mediated ferroptosis promotes pulmonary fibrosis via epigenetic repression of GPX4 and FSP1 genes

  2022cited by this paper
• Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.

  2022cited by this paper
• Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge

  2022cited by this paper
• Targeting ferroptosis as a vulnerability in pulmonary diseases

  2022cited by this paper
• The role of ferroptosis in lung cancer

  2021cited by this paper
• Preservation of small extracellular vesicles for functional analysis and therapeutic applications: a comparative evaluation of storage conditions

  2021cited by this paper
• Role of Ferroptosis in Lung Diseases

  2021cited by this paper
• Cellular Senescence in Lung Fibrosis

  2021cited by this paper
• Preclinical efficacy and clinical safety of clinical‐grade nebulized allogenic adipose mesenchymal stromal cells‐derived extracellular vesicles

  2021cited by this paper
• Fibrometabolism—An emerging therapeutic frontier in pulmonary fibrosis

  2021cited by this paper
• Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis

  2020cited by this paper
• Airway basal cells show a dedifferentiated KRT17highPhenotype and promote fibrosis in idiopathic pulmonary fibrosis

  2020cited by this paper
• Complex interplay between autophagy and oxidative stress in the development of pulmonary disease

  2020cited by this paper
• A stabilized retro-inverso peptide ligand of transferrin receptor for enhanced liposome-based hepatocellular carcinoma-targeted drug delivery.

  2019cited by this paper
• Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes.

  2019cited by this paper
• Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis

  2019cited by this paper
• Ferroptosis: Death by Lipid Peroxidation.

  2016cited by this paper
• RNAi delivery by exosome-mimetic nanovesicles - Implications for targeting c-Myc in cancer.

  2016cited by this paper
• A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

  2015cited by this paper
• Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis.

  2015cited by this paper
• Idiopathic pulmonary fibrosis.

  2014cited by this paper
• Pathogenesis of idiopathic pulmonary fibrosis.

  2014cited by this paper
• Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models

  2014cited by this paper
• Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors.

  2013cited by this paper
• Ferroptosis: an iron-dependent form of nonapoptotic cell death.

  2012cited by this paper
• An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice.

  2011cited by this paper
• Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

  2011cited by this paper
• Mechanisms of pulmonary fibrosis.

  2004cited by this paper
• Transforming growth factor beta in tissue fibrosis.

  1994cited by this paper
• Review Balancing Acts: Molecular Control of Mammalian Iron Metabolism

  year unknowncited by this paper

• No citing papers are available for this paper.